Nutropin Convenience In Depot Form Balances Lower Efficacy, FDA Finds
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The dosing convenience of Genentech’s Nutropin Depot, administered once or twice a month, is likely to "compensate for the somewhat lesser efficacy" it has compared to growth hormone (GH) products that are administered daily, FDA’s Solomon Sobel, MD, director of the Metabolic and Endocrine Drug Products Division, said in review documents.